These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9589713)
21. Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma. Morrison JC; Nylander KB; Lauer AK; Cepurna WO; Johnson E Invest Ophthalmol Vis Sci; 1998 Mar; 39(3):526-31. PubMed ID: 9501862 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma. Gramer E; Busche S; Kampik A; Parsons D Graefes Arch Clin Exp Ophthalmol; 1995 Jan; 233(1):13-20. PubMed ID: 7721118 [TBL] [Abstract][Full Text] [Related]
23. Selectivity of site of action and systemic effects of topical alpha agonists. Robin AL; Burnstein Y Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510 [TBL] [Abstract][Full Text] [Related]
24. The one-month effects of topical betaxolol, dorzolamide and apraclonidine on ocular blood flow velocities in patients with newly diagnosed primary open-angle glaucoma. Avunduk AM; Sari A; Akyol N; Oztürk O; Kapicioglu Z; Erdöl H; Imamoglu HI Ophthalmologica; 2001; 215(5):361-5. PubMed ID: 11528262 [TBL] [Abstract][Full Text] [Related]
25. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871 [TBL] [Abstract][Full Text] [Related]
26. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342 [TBL] [Abstract][Full Text] [Related]
27. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. Chung HS; Shin DH; Birt CM; Kim C; Lee D; Levin DS; Hakimzadeh R; Juzych MS Ophthalmology; 1997 Nov; 104(11):1921-5. PubMed ID: 9373127 [TBL] [Abstract][Full Text] [Related]
28. [Reduction of ocular pulse amplitude by apraclonidine--prospective double-blind, randomized clinical trial with 10 subjects]. Kuba GB; Austermann P Klin Monbl Augenheilkd; 2001 Mar; 218(3):187-91. PubMed ID: 11322056 [TBL] [Abstract][Full Text] [Related]
29. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Nagasubramanian S; Hitchings RA; Demailly P; Chuniaud M; Pannarale MR; Pecori-Giraldi J; Stodtmeister R; Parsons DG Ophthalmology; 1993 Sep; 100(9):1318-23. PubMed ID: 8371918 [TBL] [Abstract][Full Text] [Related]
30. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study. Vainio-Jylhä E; Vuori ML Graefes Arch Clin Exp Ophthalmol; 1999 Feb; 237(2):100-4. PubMed ID: 9987624 [TBL] [Abstract][Full Text] [Related]
31. Apraclonidine in the management of glaucomatocyclitic crisis. Muthusamy P Eye (Lond); 1994; 8 ( Pt 3)():367-8. PubMed ID: 7958055 [No Abstract] [Full Text] [Related]
32. Efficacy and safety of the combination therapy Pilogel/beta-blocker: interim results. Maas S; Ros FE; De Heer LJ; De Keizer RJ Doc Ophthalmol; 1989 Aug; 72(3-4):391-8. PubMed ID: 2576225 [TBL] [Abstract][Full Text] [Related]
33. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma. Sebastiani A; Parmeggiani F; Costagliola C; Ciancaglini M; D'Oronzo E; Mastropasqua L Acta Ophthalmol Scand Suppl; 2002; 236():29-30. PubMed ID: 12390124 [No Abstract] [Full Text] [Related]
34. Effects of apraclonidine on short-term outcome of glaucoma surgery. Azuara-Blanco A; Araujo SV; Lu DW; Lesk MR; Katz LJ; Spaeth GL J Glaucoma; 1996 Apr; 5(2):117-9. PubMed ID: 8795743 [TBL] [Abstract][Full Text] [Related]
35. The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. Lewis R; Perkins TW; Gangnon R; Kaufman PL; Heatley GA Ophthalmology; 1998 Dec; 105(12):2256-9. PubMed ID: 9855156 [TBL] [Abstract][Full Text] [Related]
36. Allergic contact dermatitis due to the beta-blocker betaxolol in eyedrops, with cross-sensitivity to timolol. Nino M; Napolitano M; Scalvenzi M Contact Dermatitis; 2010 May; 62(5):319-20. PubMed ID: 20536484 [No Abstract] [Full Text] [Related]
37. A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study. Simpson AJ; Gray TB; Ballantyne C Aust N Z J Ophthalmol; 1996 Feb; 24(1):39-42. PubMed ID: 8743003 [TBL] [Abstract][Full Text] [Related]
38. High incidence of topical allergic reactions to 1% apraclonidine. Feibel RM Arch Ophthalmol; 1995 Dec; 113(12):1579-80. PubMed ID: 7487638 [No Abstract] [Full Text] [Related]
39. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370 [TBL] [Abstract][Full Text] [Related]
40. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Chevrier RL; Assalian A; Duperré J; Lesk MR Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]